|
|
|
|
|
|
|
M T W Thu F |
|
3 September, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Two notes: 1) We're three weeks out from the Endpoints 11, our annual list of the most exciting startups in biotech. Join us on Sept. 24 in Boston for an evening of innovation, conversation and the unveiling of the new companies defining the future of medicine. 2) Our beloved people column, Peer Review, is on a break this week and won't publish tomorrow. |
|
|
|
Drew Armstrong |
Executive Editor, Endpoints News
@ArmstrongDrew
|
|
|
|
|
|
|
by Lei Lei Wu
|
AbbVie said its T cell engager etentamig cut the risk of disease progression or death by 60% compared with standard therapies in a Phase 3... | |
|
|
|
|
|
 |
|
|
|
by Elizabeth Cairns
|
GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on... | |
|
|
|
 |
|
|
|
by ENDPOINTS |
Plus, news about Novartis. 🤝 Pfizer turns over ADC:The New York pharma is giving Medicus Pharma co-development rights to a CD228-targeted antibody-drug conjugate known...
| |
|
|
|
|
|
